"Designing Growth Strategies is in our DNA"

U.S. Tardive Dyskinesia Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug (Deutetrabenazine, Valbenazine, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI107826

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Tardive Dyskinesia in the U.S., 2021/2022
    2. Key Industry Developments, Mergers, Acquisitions, Etc.
    3. Pipeline Analysis, Key Players
    4. Total Cost Burden for the Treatment of Tardive Dyskinesia in the U.S., 2022
    5. Regulatory & Reimbursement Scenario in the U.S.
    6. Impact of COVID-19 on the Market
  5. U.S. Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug
      1. Deutetrabenazine
      2. Valbenazine
      3. Others
    2. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Teva Pharmaceutical Industries Ltd.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      2. Neurocrine Biosciences, Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      3. Mitsubishi Chemical Group Corporation.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      4. SOM BIOTECH
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      5. Luye Pharma Group
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Tardive Dyskinesia in the U.S., 2021/2022
    2. Key Industry Developments, Mergers, Acquisitions, Etc.
    3. Pipeline Analysis, Key Players
    4. Total Cost Burden for the Treatment of Tardive Dyskinesia in the U.S., 2022
    5. Regulatory & Reimbursement Scenario in the U.S.
    6. Impact of COVID-19 on the Market
  5. U.S. Tardive Dyskinesia Therapeutics Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug
      1. Deutetrabenazine
      2. Valbenazine
      3. Others
    2. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Teva Pharmaceutical Industries Ltd.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      2. Neurocrine Biosciences, Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      3. Mitsubishi Chemical Group Corporation.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      4. SOM BIOTECH
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      5. Luye Pharma Group
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
Read Less

Figure 1:  U.S. Tardive Dyskinesia Therapeutics Market Revenue Breakdown (USD million, %), By Drug, 2022 & 2030

Figure 2:  U.S. Tardive Dyskinesia Therapeutics Market Value Share (%), By Drug, 2022 & 2030

Figure 3:  U.S. Tardive Dyskinesia Therapeutics Market Value Share (%), By Distribution Channel, 2022 & 2030

Figure 4:  U.S. Tardive Dyskinesia Therapeutics Market Share (%), 2022

Table 1:  U.S. Tardive Dyskinesia Therapeutics Market Revenue (USD million) Forecast, By Drug, 2019–2030

Table 2:  U.S. Tardive Dyskinesia Therapeutics Market Revenue (USD million) Forecast, By Distribution Channel, 2019–2030

 

U.S. Tardive Dyskinesia Therapeutics Market
  • 2019-2030
  • 2022
  • 2019-2021
  • 60
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports